CellMax-LBx Liquid Biopsy

If you are a physician and would like to collaborate with us please click here.

Personalized, Targeted Cancer Treatment

Helps your Oncologist optimize and monitor your treatments in real-time

CellMax Life’s liquid biopsy uses a routine blood sample to profile 73 genes from circulating tumor DNA (ctDNA), to identify and assess actionable genomic alterations. The test uses CellMax Life’s proprietary single-molecule-sequencing SMSEQ™ platform which has a greater than 99.999% specificity and an analytical detection limit of 0.1%.

liquid-biopsy-cancer

CellMax-LBx Liquid Biopsy Genetically Analyzes almost all Cancer Types

Target treatments, track response and monitor recurrence

CellMax-LBx Liquid Biopsy covers somatic gene alterations for solid tumors as recommended by the National Comprehensive Cancer Network and the European Society of Medical Oncology, and that are associated with FDA-approved regimens and late-phase pharmaceutical clinical trials.

Profiles 73 Genes for Mutations

Monitors gene mutations associated with cancer treatment & tumor response

There is growing evidence and medical acceptance that tumor signatures in a cancer patient’s blood – and their changes over time — can offer valuable, systemic insight into therapy selection, cancer treatment monitoring and recurrence.

CellMax Life’s comprehensive ctDNA profile of 73 genes allowing broad insight into the patient’s response to treatment by measuring the ctDNA trend throughout the course of treatment.

gene-mutations-cellmax-lbx

See List of 73 Genes Analyzed

ctdna

Non-invasive Liquid Biopsy Allows more Frequent Testing

Offers timely insight during cancer management process

The tumor sheds small DNA fragments of circulating tumor DNA (ctDNA). The tumor genes may mutate over time, either as the cancer grows, or the treatment suppresses the cancer. ctDNA gives an accurate, real-time picture of these cancer alterations.

The CellMax-LBx non-invasive blood test is typically less expensive than surgically-obtained tissue biopsies, and is more comfortable — which is especially important given the stress that cancer and associated treatments already place on patients. The liquid biopsy also overcomes problems of inherent tumor heterogeneity of cancer cells.

Being able to detect the smallest signals and trends from the ctDNA biomarker more frequently throughout the cancer management process offers timely insight and may yield information into the most effective treatment regimens tailored to the patient’s specific cancer genomic profile.

Monitor Cancer Recurrence 

More frequent monitoring helps catch potential recurrence earlier

Early study results published in Science Translational Medicine showed that the presence of ctDNA four-to-ten weeks post tumor removal could be used to predict cancer recurrence as early as stage II colon cancer. Similar clinically important findings have been seen with ctDNA for lung and breast cancer, according to the American Association for Cancer Research.

CellMax-LBx liquid biopsy allows for monitoring as frequently as needed, thus enabling earlier detection of potential cancer recurrence.

It is well-accepted that cancer survival prognosis is highest when the cancer is detected at early stages, based on the 5-year survival outlook correlated with the stage of detection.

circulating-tumor-cells-ctc

cellmax-lbx-report-excerpt-2

Actionable Reports: Your Liquid Biopsy Results

CellMax-LBx Liquid Biopsy blood test gives you a comprehensive picture of your health based on a simple blood test. The test result notes if ctDNA is detected.

The report includes relevant trend information from prior CellMax-LBx results, and a list of treatments or clinical studies that may associated with various gene mutations.

View Sample Report

CellMax SMSEQ™ Platform

Analytical specificity of ≥99.999%

CellMax Life’s liquid biopsy blood test uses next generation sequencing technology to detect gene alterations.

The patented technology, combined with years of research and development advancements enables CellMax to offer an extremely cost effective and liquid biopsy, profiling 73 genes from circulating tumor DNA (ctDNA), to identify and assess actionable genomic alterations using CellMax Life’s proprietary single-molecule-sequencing SMSEQ™ platform.

The SMSEQ platform has a greater than 99.999% specificity and an analytical detection limit of 0.1%.

Advanced Genomics

3D illustration of a method of DNA sequencing.

Medical Professionals on CellMax-LBx Liquid Biopsy

Dr. Ruey-Kuen Hsieh, MD, former-Chair, Cancer Center, MacKay Memorial Hospital.

“CellMax-LBx Liquid Biopsy will be a major factor in cancer treatment; the specificity of the assay is greater than 99.999% due to CellMax’s innovative SMSEQ platform.

“CellMax-LBx Liquid Biopsy provides a systemic gene analysis to help oncologists identify optimal targeted cancer treatments with fewer side-effects, either as a supplement to tissue biopsy, or when tissue-biopsy is not possible. Additionally, since this test requires only a routine blood draw, it enables us to track our patients’ response to treatment in real-time, as well as monitor them more frequently to warn of cancer recurrence as early as possible.”

Li-Kuan Chen, MD, Chair, Department of Clinical Pathology, Hualien Tzu Chi Hospital

An adult male patient reported into the emergency room & was diagnosed with stage-II lung cancer.

“CellMax-LBx liquid biopsies were conducted separately on a pleural effusion sample and a routine peripheral blood-sample — both revealed an actionable EGFR mutation. Additionally, biopsies revealed a TP53 mutation for which the CellMax-LBx report identified a drug in Phase-3 trial.

“As a Pathologist, I worked with the patient’s Oncologist to utilize this combined information to tailor the best treatment for the patient. We will continue to use CellMax-LBx to monitor the patient’s response and progress.”